STOCK TITAN

[SCHEDULE 13G/A] BICYCLE THERAPEUTICS PLC Amended Passive Investment Disclosure

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Westfield Capital Management Company, L.P. has reported beneficial ownership of 3,016,026 shares of Bicycle Therapeutics plc common stock, representing 6.04% of the class as of 12/31/2025.

Westfield has sole power to vote 2,801,276 shares and sole power to dispose of 3,016,026 shares, with no shared voting or dispositive power. The shares are owned of record by Westfield’s investment advisory clients, who are entitled to dividends and sale proceeds. Westfield states the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of the company.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Westfield Capital Management Company, L.P.
Signature:Brandi McMahon
Name/Title:Vice President, Deputy Chief Compliance Officer
Date:02/10/2026
Bicycle Therapeutics Limited

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Latest SEC Filings

BCYC Stock Data

384.30M
49.19M
1.4%
88.35%
2.29%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
CAMBRIDGE